UK Clinical Trials Market Size & Outlook, 2025-2033
Related Markets
UK clinical trials market highlights
- The UK clinical trials market generated a revenue of USD 3,508.5 million in 2024 and is expected to reach USD 6,948.9 million by 2033.
- The UK market is expected to grow at a CAGR of 8.1% from 2025 to 2033.
- In terms of segment, phase iii was the largest revenue generating phase in 2024.
- Phase IV is the most lucrative phase segment registering the fastest growth during the forecast period.
Clinical trials market data book summary
| Market revenue in 2024 | USD 3,508.5 million |
| Market revenue in 2033 | USD 6,948.9 million |
| Growth rate | 8.1% (CAGR from 2025 to 2033) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase IV |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Thermo Fisher Scientific Inc, Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, PAREXEL, Wuxi AppTec Co Ltd, Labcorp Holdings Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Pfizer Inc, Caidya |
Other key industry trends
- In terms of revenue, UK accounted for 4.1% of the global clinical trials market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany clinical trials market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 6,948.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Trials Market Scope
Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Caidya | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | https://www.caidya.com |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | https://www.syneoshealth.com/ |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | http://www.parexel.com |
| SGS AG | View profile | 103193 | 1 Place des Alpes, P.O. Box 2152, Geneva, Switzerland, CH-1211 | https://www.sgs.com |
| IQVIA Holdings Inc | View profile | 87000 | 2400 Ellis Road, Durham, NC, United States, 27703 | https://www.iqvia.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
UK clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 56.72% in 2024. Horizon Databook has segmented the UK clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
The main drivers of the region’s growth include the presence of various multinational pharmaceutical companies, significant R&D spending, healthcare research, and rapidly evolving CROs focused on phases I to IV developments of new drugs & devices.
Furthermore, with the healthcare data asset, competitive & collaborative research base, and substantial clinical research & NHS translation capabilities, the UK is an attractive environment for clinical trials & pioneering research.
In addition, the presence of major companies, such as Merck KGaA and Parexel International Corporation, offer CRO services to various biotechnological & pharmaceutical & medical devices companies, contributing to market growth. The increasing number of projects are likely to drive the clinical trials market in the UK.
Reasons to subscribe to UK clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK clinical trials market databook
-
Our clientele includes a mix of clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK clinical trials market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
UK clinical trials market size, by phase, 2021-2033 (US$M)
UK Clinical Trials Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
